Update on the treatment of cutaneous T-cell lymphoma (CTCL): Focus on vorinostat

References

• AlmenaraJRosatoRGrantS2002Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA)Leukemia1613314312094258
   PubMed Web of Science ®Google Scholar
• ApisarnthanaraxNTalpurRWardS2004Tazarotene 0.1% gel for refractory mycosis fungoides lesions: an open-label pilot studyJ Am Acad Dermatol50600715034511
   PubMed Web of Science ®Google Scholar
• AssafCBagotMDrummerR2006Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinionBr J Dermatol155261616882161
   PubMed Web of Science ®Google Scholar
• AxelrodPILorberBVonderheidEC1992Infections complicating mycosis fungoides and Sezary syndromeJAMA267135481740857
   PubMed Web of Science ®Google Scholar
• BergerCLHanlonDKanadaD2002The growth of cutaneous T-cell lymphoma is stimulated by immature dendritic cellsBlood9929293911929784
   PubMed Web of Science ®Google Scholar
• BlanderGGuarenteL2004The Sir2 family of protein deacetylasesAnnu Rev Biochem734173515189148
   PubMed Web of Science ®Google Scholar
• BoldenJEPeartMJJohnstoneRW2006Anticancer activities of histone deacetylase inhibitorsNat Rev Drug Discov57698416955068
   PubMed Web of Science ®Google Scholar
• BrenemanDDuvicMKuzelT2002Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphomaArch Dermatol1383253211902983
   PubMed Web of Science ®Google Scholar
• ButlerLMAgusDBMarksPA2000Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivoCancer Res6051657011016644
   PubMed Web of Science ®Google Scholar
• ButlerLMAgusDBScherHI2000Suberoylanilide hydoxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivoCancer Res6051657011016644
   PubMed Web of Science ®Google Scholar
• ButlerLMLiapisVBouralexisS2006The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAILInt J Cancer1199445416550602
   PubMed Web of Science ®Google Scholar
• ButlerLMZhouXXuWS2002The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxinProc Natl Acad Sci USA9911700512189205
   PubMed Web of Science ®Google Scholar
• CohenLAAminSMarksPA1999Chemoprevention of carcinogen-induced mammary tumorigenesis by the hybrid polar cytodifferentiation agent, suberanilohydroxamic acid (SAHA)Anticancer Res194999500510697502
   PubMed Web of Science ®Google Scholar
• CohenLAMarksPARifkindRA2002Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, suppresses the growth of carcinogen-induced mammary tumorsAnticancer Res22149750412168829
   PubMed Web of Science ®Google Scholar
• de RuijterAJvan GennipAHCaronHN2003Histone deacetylases (HDACs): characterization of the classical HDAC familyBiochem J3707374912429021
   PubMed Web of Science ®Google Scholar
• DeethsMJChapmanJTDellavalleRP2005Treatment of patch and plaque stage mycosis fungoides with imiquimod 5% creamJ Am Acad Dermatol522758015692473
   PubMed Web of Science ®Google Scholar
• DesaiDDasACohenL2003Chemopreventive efficacy of suberoylanilide hydroxamic acid (SAHA) against 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced lung tumorigenesis in female A/J miceAnticancer Res231A49950312680257
   PubMed Web of Science ®Google Scholar
• DiwanAHPrietoVGHerlingM2005Primary Sezary syndrome commonly shows low grade cytologic appearance and absence of epidermotropismAm J Clin Pathology12351015
   PubMed Web of Science ®Google Scholar
• DuvicMMartinAGKimY2001Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphomaArch Dermatol1375819311346336
   PubMed Web of Science ®Google Scholar
• DuvicMZhangC2006Clinical and laboratory experience of vorinostat (suberoylanilide hydroxamic acid) in the treatment of cutaneous T-cell lymphomaBr J Cancer95Suppl 1S1319
   PubMed Web of Science ®Google Scholar
• DuvicMTalpurRNiX2007Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)Blood10931916960145
   PubMed Web of Science ®Google Scholar
• FossFDemierreMFDivenutiG2005A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphomaBlood106454715811959
   PubMed Web of Science ®Google Scholar
• FurumaiRMatsuyamaAKobashiN2002FK228 (Depsipeptide) as a natural prodrug that inhibits class I histone deacetylasesCancer Res6249162112208741
   PubMed Web of Science ®Google Scholar
• Garcia-ManeroGYangHSanchez-GonzalezB2005Final results of a phase I study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with leukemia and myelodysplastic syndrome [abstract]Blood106785a
   Web of Science ®Google Scholar
• GiardiMHealdPWWilsonLD2004The pathogenesis of mycosis fungoidesN Engl J Med35019788815128898
   PubMed Web of Science ®Google Scholar
• GoreSDCarducciMA2000Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitorsExp Opin Invest Drugs9292334
   PubMed Web of Science ®Google Scholar
• GregorettiIVLeeYMGoodsonHV2004Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysisJ Mol Biol338173115050820
   PubMed Web of Science ®Google Scholar
• GuiCYNgoLXuWS2004Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1Proc Natl Acad Sci USA1011241614734806
   PubMed Web of Science ®Google Scholar
• GuoFSiguaCTaoJ2004Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cellsCancer Res642580915059915
   PubMed Web of Science ®Google Scholar
• HeLZTolentinoTGraysonP2001Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemiaJ Clin Invest10813213011696577
   PubMed Web of Science ®Google Scholar
• HeiderUKaiserMSterzJ2006Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphomaEur J Haematol76425016343270
   PubMed Web of Science ®Google Scholar
• JackowCMCatherJCHearneV1997Association of erythrodermic cutaneous T-cell lymphoma, superantigen-positive Staphylococcus aureus, and oligoclonal T-cell receptor V beta gene expansionBlood8932408978274
   PubMed Web of Science ®Google Scholar
• JackowCMMcHamJBFrissA1996HLA-DR5 and DQB1*03 class II alleles are associated with cutaneous T-cell lymphomaJ Invest Dermatol10737368751973
   PubMed Web of Science ®Google Scholar
• KazakovDVBurgGKempfW2004Clinicopathological spectrum of mycosis fungoidesJ Eur Acad Dermatol Venereol1839741515196152
   PubMed Web of Science ®Google Scholar
• KellyWKMarksPA2005Drug insight: Histone deacetylase inhibitors-development of the new targeted anticancer agent suberoylanilide development of the new targeted anticancer agent suberoylanilide hydroxamic acidNat Clin Paract Oncol21507
   PubMedGoogle Scholar
• KellyWKO’ConnorOAKrugLM2005Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancerJ Clin Oncol2339233115897550
   PubMed Web of Science ®Google Scholar
• KellyWKRichonVMO’ConnorO2003Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenouslyClin Cancer Res910 Pt 135788814506144
   PubMed Web of Science ®Google Scholar
• KimEJHessSRichardsonSK2005Immunopathogenesis and therapy of cutaneous T cell lymphomaJ Clin Invest11579881215841167
   PubMed Web of Science ®Google Scholar
• KrakenWAWardSRDuvicM2003Bexarotene is a new treatment option for lymphomatoid papulosisDermatology206142712592082
   PubMed Web of Science ®Google Scholar
• LainTTalpurRDuvicM2003Long-term control of mycosis fungoides of the hands with topical bexaroteneInt J Dermatol422384112653924
   PubMed Web of Science ®Google Scholar
• LakshmikanthanVKaddour-DjebbarILewisRW2006SAHA-sensitized prostate cancer cells to TNFalpha-related apoptosis-inducing ligand(TRAIL): mechanisms leading to synergistic apoptosisInt J Cancer119221816450389
   PubMed Web of Science ®Google Scholar
• LedentVVervoortM2006Comparative genomics of class 4 histone deacetylases indicates a complex evolutionary historyBMC Biol42416884538
   PubMed Web of Science ®Google Scholar
• LimHWEdelsonRL1995Photopheresis for the treatment of cutaneous T-cell lymphomaHematol Oncol Clin North Am91117268522488
   PubMed Web of Science ®Google Scholar
• LindemannRKGabrielliBJohnstoneRW2004Histone-deacetylase inhibitors for the treatment of cancerCell Cycle37798815153801
   PubMed Web of Science ®Google Scholar
• MarchionDCBicakuEDaudAI2004Sequence-specific potentiation oftopoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilidehydroxamic acidJ Cell Biochem922233715108350
   PubMed Web of Science ®Google Scholar
• MarchionDOBicakuEDaudAI2004Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamine acidJ Cell Biochem922233715108350
   PubMed Web of Science ®Google Scholar
• MarksPRifkindRARichonVM2001Histone deacetylases and cancer: causes and therapiesNat Rev Cancer119420211902574
   PubMed Web of Science ®Google Scholar
• MarksPABreslowR2007Dimethyl sulfoxide to vorinostat: Development of this histone deacetylase inhibitor as an anti-cancer drugNature Biotechnology258490
   PubMed Web of Science ®Google Scholar
• MarksPADokmanovicM2005Histone deacetylase inhibitors: discovery and development as anticancer agentsExpert Opin Investig Drugs141497511
   PubMed Web of Science ®Google Scholar
• MarksPAJiangX2005Histone deacetylase inhibitors in programmed cell death and cancer therapyCell Cycle45495115738652
   PubMed Web of Science ®Google Scholar
• McGinnisKSUbrianiRNewtonS2005The addition of interferon gamma to oral bexarotene therapy with photopheresis for Sézary syndromeArch Dermatol1411176816172331
   PubMed Web of Science ®Google Scholar
• MeiSHoADMahlknechtU2004Role of histone deacetylase inhibitors in the treatment of cancer (Review)Int J Oncol25150915547685
   PubMed Web of Science ®Google Scholar
• MillerABHoogstratenBStaquetM1981Reporting results of cancer treatmentCancer47207147459811
   PubMed Web of Science ®Google Scholar
• MoradeiOMarounCRPaquinI2005Histone deacetylase inhibitors: latest developments, trends, and prospectsCurr Med Chem Anticancer Agents55296016178777
   PubMedGoogle Scholar
• NiXZhangCTalpurR2005Resistance to activation-induced cell death and bystander cytotoxicity via the Fas/Fas ligand pathway are implicated in the pathogenesis of cutaneous T cell lymphomasJ Invest Dermatol1247415015816832
   PubMed Web of Science ®Google Scholar
• NimmanapalliRFuinoLStobaughC2003Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cellsBlood1013236912446442
   PubMed Web of Science ®Google Scholar
• OckerMAlajatiAGanslmayerM2005The histone-deacetylase inhibitor SAHA potentiates proapoptotic effects of 5-fluorouracil and irinotecan in hepatoma cellsJ Cancer Res Clin Oncol1313859415754201
   PubMed Web of Science ®Google Scholar
• O’ConnorOAHeaneyMLSchwartzL2006Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignanciesJ Clin Oncol241667316330674
   PubMed Web of Science ®Google Scholar
• O’ConnorOA2005Developing new drugs for the treatment of lymphomaEur J HaematolSuppl 66150816004608
   PubMed Web of Science ®Google Scholar
• OlsenEDuvicMFrankelA2001Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphomaJ Clin Oncol193768811208829
   PubMed Web of Science ®Google Scholar
• OlsenEKimYHKuzelT2007Phase IIB. Multicenter trial of Vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphomaJ Clin Oncol618 Epub
   Web of Science ®Google Scholar
• PicardoDAQuerfeldCGuitartJ2004Cutaneous T-cell lymphoma: a paradigm for biological therapiesLeukemia and Lymphoma4517556515223633
   PubMed Web of Science ®Google Scholar
• PiekarzRBatesS2004A review of depsipeptide and other histone deacetylase inhibitors in clinical trialsCurr Pharm Des1022899815279609
   PubMed Web of Science ®Google Scholar
• PiekarzRLRobeyRSandorV2001Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case reportBlood982865811675364
   PubMed Web of Science ®Google Scholar
• PiekarzRLRobeyRWZhanZ2004T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistanceBlood10346364314996704
   PubMed Web of Science ®Google Scholar
• PiekarzRLRobeyRWZhanZ2004T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide onmolecular markers, therapeutic targets, and mechanisms of resistanceBlood10346364314996704
   PubMed Web of Science ®Google Scholar
• PrinceHMGeorgeDJJohnstoneR2006LBH589 a novel deacetylase inhibitor (DACi), treatment of patients with cutaneous T-cell lymphoma (CTCL): skin gene expression profiles in the first 24 hours related to clinical response following therapyPresented at 2006 ASH Annual MeetingOrlando, FL
   Google Scholar
• QuerfeldCRosenSTGuitartJ2005The spectrum of cutaneous T-cell lymphomas: new insights into biology and therapyCurrent Opinion in Hematology12273815928483
   PubMedGoogle Scholar
• ReddyPMaedaYHotaryK2004Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effectProc Natl Acad Sci USA1013921615001702
   PubMed Web of Science ®Google Scholar
• RichonVMEmilianiSVerdinE1998A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylasesProc Natl Acad Sci USA95300379501205
   PubMed Web of Science ®Google Scholar
• RichonVMSandhoffTWRifkindRA2000Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylationProc Natl Acad Sci USA97100141910954755
   PubMed Web of Science ®Google Scholar
• RookAHGottliebSLWolfeJT1997Pathogenesis of cutaneous T-cell lymphoma: implications for the use of recombinant cytokines and photopheresisClin Exp Immunol107Suppl 116209020930
   PubMed Web of Science ®Google Scholar
• RosatoRRAlmenaraJADaiY2003Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cellsMol Cancer Ther212738414707268
   PubMed Web of Science ®Google Scholar
• SakajiriSKumagaiTKawamataN2005Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell linesExp Hematol33536115661398
   PubMed Web of Science ®Google Scholar
• SandorVSenderowiczAMertinsS2000P21-dependent G1 arrest withdownregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylaseinhibitor FR901228British Journal of Cancer838172510952788
   PubMed Web of Science ®Google Scholar
• ShaoYGaoZMarksPA2004Apoptotic and autophagic cell death induced by histone deacetylase inhibitorsProc Natl Acad Sci USA10118030515596714
   PubMed Web of Science ®Google Scholar
• ShimakageMSasagawaTKawaharaK2001Expression of Epstein-Barr virus in cutaneous T-cell lymphoma including mycosis fungoidesInt J Cancer922263111291050
   PubMed Web of Science ®Google Scholar
• SomechRIzraeliSSimonJ2004Histone deacetylase inhibitors – a new tool to treat cancerCancer Treat Rev304617215245778
   PubMed Web of Science ®Google Scholar
• SommerVHClemmensenOJNielsenO2004In vivo activation of STAT3 in cutaneous T-cell lymphoma. Evidence for an antiapoptotic function of STAT3Leukemia1812889515141228
   PubMed Web of Science ®Google Scholar
• SteeleNVidalL2005A phase 1 pharmacokinetic (PK) andpharmacodynamic (PD) study of the histone deacetylase (HDAC) inhibitor PXD101in patients (pts) with advanced solid tumoursJ Clin Oncol2316 Suppl3035
   Web of Science ®Google Scholar
• TanRSButterworthCMMcLaughlinH1974Mycosis fungoides-a disease of antigen persistenceBr J Dermatol91607164281316
   PubMed Web of Science ®Google Scholar
• TokuraYYagiHOhshimaA1995Cutaneous colonization with staphylococci influences the disease activity of Sezary syndrome: a potential role for bacterial superantigensBr J Dermatol1336127669641
   PubMed Web of Science ®Google Scholar
• TurksonJ2004STAT proteins as novel targets for cancer drug discoveryExpert Opin Ther Targets84092215469392
   PubMed Web of Science ®Google Scholar
• UngerstedtJSSowaYXuWS2005Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitorsProc Natl Acad Sci USA102673815637150
   PubMed Web of Science ®Google Scholar
• VegaFLuthraRMedeirosLJ2002Clonal heterogeneity in mycosis fungoides and its relationship to clinical courseBlood10033697312384439
   PubMed Web of Science ®Google Scholar
• VranaJADeckerRHJohnsonCR1999Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53Oncogene1870162510597302
   PubMed Web of Science ®Google Scholar
• ZhangCRichonVNiX2005Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic actionJ Invest Dermatol12510455216297208
   PubMed Web of Science ®Google Scholar